uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001940:Breast / Q000378:metabolism*; D001943:Breast Neoplasms / Q000209:etiology / Q000517:prevention & control*; D000068579:Celecoxib; D015232:Dinoprostone / Q000097:blood / Q000378:metabolism*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009558:Nipples / Q000737:chemistry; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood / Q000378:metabolism*; D017698:Postmenopause; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D012307:Risk Factors; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D015854:Up-Regulation; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood / Q000378:metabolism*
D017395:Plasminogen Activator Inhibitor 1; D011720:Pyrazoles; D013449:Sulfonamides; D014568:Urokinase-Type Plasminogen Activator; D000068579:Celecoxib; D015232:Dinoprostone